Idiopathic pulmonary fibrosis, a relentless scarring disease of the lungs that slowly robs patients of the ability to breathe, has long defied the best efforts of medical science. Current anti-fibrotic drugs can slow the disease down, but they cannot undo the damage that has already been done. Now, a team of researchers led by Wen-Yu Zhao and Lan Wang of Henan Normal University, working with colleagues in China, Canada and South Korea, has uncovered a previously underappreciated molecular engine that appears to drive the fibrotic process forward. Writing in the journal Cellular and Molecular Life Sciences, the team describes how a long non-coding RNA molecule known as H19 helps orchestrate the cellular changes that turn ordinary lung fibroblasts into the scar-producing cells that define the disease. The finding, published as an open-access article on 14 September 2026, points to a chain of molecular events that could become a target for entirely new kinds of therapy.
The scale of the unmet need is difficult to overstate. Idiopathic pulmonary fibrosis, or IPF, is a chronic, progressive interstitial lung disorder that is ultimately lethal, and the treatment options available today are very limited. The two approved anti-fibrotic drugs can only halt disease progression; they cannot reverse fibrotic tissue damage that has already been established. Once the lung architecture is remodeled by dense scar tissue, the loss of function is effectively permanent, and many patients eventually require a lung transplant to survive. This stark therapeutic ceiling is why researchers have increasingly turned their attention to the fundamental molecular machinery inside lung cells, searching for points of intervention that go beyond merely slowing the disease down.
One of the most intriguing classes of molecules to emerge from that search is the long non-coding RNAs, or lncRNAs. These are RNA transcripts that are copied from the genome but, unlike messenger RNAs, are not translated into proteins. For decades they were dismissed as genetic noise, but it is now clear that many of them act as sophisticated regulators of cellular behavior, influencing which genes are switched on or off and how cells respond to external signals. In fibrotic diseases, lncRNAs have appeared as important regulators of the scarring process. Yet the specific role of one prominent lncRNA, H19, in IPF remained incompletely understood, and it was this gap in knowledge that the new study set out to fill.
The researchers began with a straightforward but crucial observation: H19 is significantly upregulated in lung tissues from patients with IPF, in fibroblasts derived from those patients, and in human lung fibroblasts that have been activated in the laboratory by transforming growth factor beta 1, or TGF-β1, the master pro-fibrotic cytokine. Fibroblasts are the connective tissue cells of the lung, and in IPF they undergo a dramatic transformation into myofibroblasts, contractile cells that churn out collagen and other extracellular matrix proteins, stiffening the lung like scar tissue in a healing wound that never stops healing. The fact that H19 levels rise consistently in patient tissue and in experimentally activated fibroblasts suggested that the molecule is not a bystander but an active participant in this transformation.
To understand how H19 exerts its influence, the team dug into the molecule’s mechanism of action, and what they found is a textbook example of a regulatory strategy known as the competing endogenous RNA model, or ceRNA. In this model, a long non-coding RNA acts as a molecular sponge, soaking up and sequestering microRNAs, which are tiny RNA fragments that normally suppress gene expression by binding to target messenger RNAs. The researchers demonstrated that H19 specifically sequesters a microRNA called miR-103a-3p. Under normal circumstances, miR-103a-3p binds to and inhibits a bona fide target gene called TRIOBP, keeping the production of the TRIOBP protein in check. But when H19 is abundant, it mops up the microRNA, relieving that inhibitory effect and allowing TRIOBP levels to climb.
The consequences of that climb are profound. The study shows that the upregulation of TRIOBP triggers the PI3K/AKT signaling pathway, a well-known intracellular cascade that functions as a central control hub for cell survival, growth and metabolism. Once activated, this pathway facilitates the conversion of fibroblasts into myofibroblasts, the defining cellular event of pulmonary fibrosis. It also enhances the proliferative and migratory capacities of these cells, allowing them to multiply and spread through the lung tissue, and it confers resistance to programmed cell death, meaning the scar-forming cells survive when they should be eliminated. In effect, the H19/miR-103a-3p/TRIOBP axis rewires fibroblasts into persistent, invasive, scar-producing machines, all funneled through the activation of PI3K/AKT.
Crucially, the team did not merely correlate these molecular changes with disease; they perturbed them directly and watched what happened. When the researchers knocked down H19, or when they overexpressed miR-103a-3p to compensate for the sponge effect, the fibrotic phenotypes were attenuated: the fibroblasts became less myofibroblast-like, less proliferative, less migratory and less resistant to cell death. Conversely, when the researchers inhibited miR-103a-3p, they reversed the anti-fibrotic effect of H19 silencing, restoring the pro-fibrotic behavior of the cells. This series of gain-of-function and loss-of-function experiments establishes a clear causal chain rather than a mere association, and it demonstrates that the pro-fibrotic effects of H19 are mediated primarily through the sequestration of miR-103a-3p and the consequent activation of TRIOBP and the PI3K/AKT cascade.
The elegance of the ceRNA mechanism also carries practical implications for drug development. Traditional drugs target proteins, but the molecules in this pathway, H19 and miR-103a-3p, are RNAs, and the past decade has seen remarkable progress in RNA-based therapeutics, from antisense oligonucleotides to small interfering RNAs that can be designed to silence specific transcripts. A therapy aimed at reducing H19, or at delivering synthetic miR-103a-3p to restore the suppressed brake on TRIOBP, would operate at a level of the disease process that current anti-fibrotic drugs do not touch. The authors suggest that therapeutic intervention aimed at this pathway could offer a promising strategy for IPF, and the fact that the axis promotes proliferation, migration and survival resistance simultaneously means that blocking it could attack the disease from several directions at once.
There are, of course, important caveats and steps that remain before such a strategy could reach patients. The study was supported by the National Natural Science Foundation of China and several regional Chinese research programs, and the human specimens used were obtained with ethical approval from the First Affiliated Hospital of Zhengzhou University, with informed consent from all participants. Translating the findings into a clinical intervention will require demonstrating that the H19/miR-103a-3p/TRIOBP axis can be safely modulated in living lungs, that delivering RNA-targeted drugs to fibrotic lung tissue is feasible, and that suppressing the pathway does not interfere with normal wound healing elsewhere in the body. The PI3K/AKT pathway, in particular, is used by many cell types for many purposes, so any therapeutic approach will need to be carefully calibrated to avoid broad systemic effects.
Even so, the study represents a meaningful advance in understanding why the lungs of IPF patients keep scarring long after an injury has passed. By delineating the H19/miR-103a-3p/TRIOBP signaling axis as a pivotal promoter of fibrotic processes in the lung, the researchers have converted a mysterious regulatory RNA into a concrete, mechanistically defined link in the chain that leads from activated fibroblast to lethal pulmonary scar. For a disease in which existing drugs can only slow the clock, the identification of a druggable circuit that sits upstream of myofibroblast transformation, proliferation, migration and survival offers something genuinely new: a molecular explanation of the disease’s persistence, and a plausible route toward therapies that might one day do more than merely delay the inevitable.
Subject of Research: The role of the lncRNA H19/miR-103a-3p/TRIOBP axis in activating PI3K/AKT signaling and driving fibroblast-to-myofibroblast transformation in idiopathic pulmonary fibrosis
Article Title: H19 promotes the development of idiopathic pulmonary fibrosis by modulating TRIOBP to stimulate the PI3K/AKT signaling pathway
Article References: Zhao, W.-Y., Zhao, H., Yang, T., Huang, S., Chen, Y., Li, Z., Leask, A., Kim, G.-Y., Song, J., Yu, G., & Wang, L. (2026). H19 promotes the development of idiopathic pulmonary fibrosis by modulating TRIOBP to stimulate the PI3K/AKT signaling pathway. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06444-2
Image Credits: AI Generated
DOI: 10.1007/s00018-026-06444-2
Keywords: idiopathic pulmonary fibrosis, long non-coding RNA, H19, miR-103a-3p, TRIOBP, PI3K/AKT signaling, competing endogenous RNA, myofibroblast, TGF-beta 1, lung fibrosis, RNA therapeutics, fibroblast activation
Cite Scienmag News
APA
MLA
Chicago
Drew Townsend. (October 4, 2026). Hidden RNA Switch Drives Deadly Scarring of the Lungs, Study Finds. Scienmag. https://scienmag.com/hidden-rna-switch-drives-deadly-scarring-of-the-lungs-study-finds/
Drew Townsend. “Hidden RNA Switch Drives Deadly Scarring of the Lungs, Study Finds.” Scienmag, 4 October 2026, https://scienmag.com/hidden-rna-switch-drives-deadly-scarring-of-the-lungs-study-finds/. Accessed 4 October 2026.
Drew Townsend. “Hidden RNA Switch Drives Deadly Scarring of the Lungs, Study Finds.” Scienmag. October 4, 2026. https://scienmag.com/hidden-rna-switch-drives-deadly-scarring-of-the-lungs-study-finds/
Copy citation
Download RIS
Tags: cellular changes in lung fibrosiscompeting endogenous RNAfibroblast activationfibrosis research breakthroughsfibrosis treatment advancementsH19Idiopathic pulmonary fibrosisLong non-coding RNAlung fibroblast activationlung fibrosislung scarringmiR-103a-3pmolecular biology of lung scarringmolecular mechanisms of fibrosismyofibroblastnon-coding RNA H19novel therapeutic targets for IPFPI3K-AKT signalingpotential gene therapy for IPFRNA therapeuticsRNA-driven fibrotic processTGF-beta 1TRIOBP
